{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T22:43:48Z","timestamp":1791931428108,"version":"4.3.4"},"reference-count":213,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology &amp; Therapeutics"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.pharmthera.2017.02.029","type":"journal-article","created":{"date-parts":[[2017,2,14]],"date-time":"2017-02-14T09:31:46Z","timestamp":1487064706000},"page":"1-16","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":139,"special_numbering":"C","title":["Myotoxicity of statins: Mechanism of action"],"prefix":"10.1016","volume":"175","author":[{"given":"Patrick","family":"du Souich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghislaine","family":"Roederer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Dufour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2017.02.029_bb0005","doi-asserted-by":"crossref","first-page":"19587","DOI":"10.1074\/jbc.M408862200","article-title":"Exercise stimulates Pgc-1alpha transcription in skeletal muscle through activation of the p38 MAPK pathway","volume":"280","author":"Akimoto","year":"2005","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0010","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/clpt.2014.121","article-title":"Phenotype standardization for statin-induced myotoxicity","volume":"96","author":"Alfirevic","year":"2014","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0015","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1152\/physrev.00015.2007","article-title":"Skeletal muscle fatigue: Cellular mechanisms","volume":"88","author":"Allen","year":"2008","journal-title":"Physiological Reviews"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0020","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.mayocp.2014.08.021","article-title":"Effects of coenzyme Q10 on statin-induced myopathy: A meta-analysis of randomized controlled trials","volume":"90","author":"Banach","year":"2015","journal-title":"Mayo Clinic Proceedings"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0025","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.phrs.2015.07.008","article-title":"Statin therapy and plasma coenzyme Q10 concentrations\u2014A systematic review and meta-analysis of placebo-controlled trials","volume":"99","author":"Banach","year":"2015","journal-title":"Pharmacological Research"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0064069","article-title":"Estrone-3-sulphate, a potential novel ligand for targeting breast cancers","volume":"8","author":"Banerjee","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0035","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/tpj.2011.59","article-title":"Genetic variation in the ABCC2 gene is associated with dose decreases or switches to other cholesterol-lowering drugs during simvastatin and atorvastatin therapy","volume":"13","author":"Becker","year":"2013","journal-title":"The Pharmacogenomics Journal"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0040","doi-asserted-by":"crossref","first-page":"4228","DOI":"10.1074\/jbc.M704332200","article-title":"Modest PGC-1alpha overexpression in muscle in vivo is sufficient to increase insulin sensitivity and palmitate oxidation in subsarcolemmal, not intermyofibrillar, mitochondria","volume":"283","author":"Benton","year":"2008","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0045","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1152\/physiolgenomics.90217.2008","article-title":"PGC-1alpha increases skeletal muscle lactate uptake by increasing the expression of MCT1 but not MCT2 or MCT4","volume":"35","author":"Benton","year":"2008","journal-title":"Physiological Genomics"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0050","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.bbrc.2004.08.084","article-title":"Monocarboxylate transporters in subsarcolemmal and intermyofibrillar mitochondria","volume":"323","author":"Benton","year":"2004","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0055","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s00228-014-1801-z","article-title":"Impact of ABCG2 and SLCO1B1 polymorphisms on pharmacokinetics of rosuvastatin, atorvastatin and simvastatin acid in Caucasian and Asian subjects: a class effect?","volume":"71","author":"Birmingham","year":"2015","journal-title":"European Journal of Clinical Pharmacology"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0060","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s004210100516","article-title":"The expression of lactate transporters (MCT1 and MCT4) in heart and muscle","volume":"86","author":"Bonen","year":"2001","journal-title":"European Journal of Applied Physiology"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0065","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s00204-014-1378-4","article-title":"Simvastatin induces mitochondrial dysfunction and increased atrogin-1 expression in H9c2 cardiomyocytes and mice in vivo","volume":"90","author":"Bonifacio","year":"2016","journal-title":"Archives of Toxicology"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0070","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1016\/j.bbamcr.2015.04.010","article-title":"The AKT\/mTOR signaling pathway plays a key role in statin-induced myotoxicity","volume":"1853","author":"Bonifacio","year":"2015","journal-title":"Biochimica et Biophysica Acta-Molecular Cell Research"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0075","article-title":"IGF-1 prevents simvastatin-induced myotoxicity in C2C12 myotubes","author":"Bonifacio","year":"2016","journal-title":"Archives of Toxicology"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0080","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.ejps.2014.09.007","article-title":"Predicting carrier-mediated hepatic disposition of rosuvastatin in man by scaling from individual transfected cell-lines in vitro using absolute transporter protein quantification and PBPK modeling","volume":"65","author":"Bosgra","year":"2014","journal-title":"European Journal of Pharmaceutical Sciences"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0085","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1093\/eurheartj\/ehr224","article-title":"Opposite effects of statins on mitochondria of cardiac and skeletal muscles: A 'mitohormesis' mechanism involving reactive oxygen species and PGC-1","volume":"33","author":"Bouitbir","year":"2012","journal-title":"European Heart Journal"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0090","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1089\/ars.2014.6190","article-title":"Statins trigger mitochondrial reactive oxygen species-induced apoptosis in glycolytic skeletal muscle","volume":"24","author":"Bouitbir","year":"2016","journal-title":"Antioxidants & Redox Signaling"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0095","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.jacl.2016.05.003","article-title":"Metabolic syndrome is associated with muscle symptoms among statin users","volume":"10","author":"Brinton","year":"2016","journal-title":"Journal of Clinical Lipidology"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0100","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/MOL.0000000000000038","article-title":"Cholesterol precursors: More than mere markers of biosynthesis","volume":"25","author":"Brown","year":"2014","journal-title":"Current Opinion in Lipidology"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0105","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/tpj.2010.92","article-title":"Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin","volume":"12","author":"Brunham","year":"2012","journal-title":"The Pharmacogenomics Journal"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0110","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jsbmb.2013.02.013","article-title":"Role of VDR in 1\u03b1,25-dihydroxyvitamin D3-dependent non-genomic activation of MAPKs, Src and Akt in skeletal muscle cells","volume":"136","author":"Buitrago","year":"2013","journal-title":"The Journal of Steroid Biochemistry and Molecular Biology"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0120","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/978-3-642-14541-4_2","article-title":"In vitro and in vivo evidence of the importance of organic anion transporters (OATs) in drug therapy","volume":"201","author":"Burckhardt","year":"2011","journal-title":"Handbook of Experimental Pharmacology"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0125","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.taap.2016.06.032","article-title":"Statin-induced myotoxicity is exacerbated by aging: A biophysical and molecular biology study in rats treated with atorvastatin","volume":"306","author":"Camerino","year":"2016","journal-title":"Toxicology and Applied Pharmacology"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0130","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1038\/gim.2014.41","article-title":"Genetic factors affecting statin concentrations and subsequent myopathy: a HuGENet systematic review","volume":"16","author":"Canestaro","year":"2014","journal-title":"Genetics in Medicine"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0135","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1096\/fj.08-128843","article-title":"Statin-induced muscle damage and atrogin-1 induction is the result of a geranylgeranylation defect","volume":"23","author":"Cao","year":"2009","journal-title":"The FASEB Journal"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0140","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/clpt.2013.161","article-title":"SLCO1B1 genetic variant associated with statin-induced myopathy: Proof-of-concept study using the clinical practice research datalink","volume":"94","author":"Carr","year":"2013","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0145","doi-asserted-by":"crossref","first-page":"277","DOI":"10.2478\/acph-2013-0022","article-title":"Drug interactions with statins","volume":"63","author":"Causevic-Ramosevac","year":"2013","journal-title":"Acta Pharmaceutica"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0150","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1161\/CIRCGENETICS.111.961144","article-title":"Genetic determinants of statin-induced low-density lipoprotein cholesterol reduction: The justification for the use of statins in prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) trial","volume":"5","author":"Chasman","year":"2012","journal-title":"Circulation. Cardiovascular Genetics"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0155","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s40262-013-0075-4","article-title":"Drug-drug interactions between HMG-CoA reductase inhibitors (statins) and antiviral protease inhibitors","volume":"52","author":"Chauvin","year":"2013","journal-title":"Clinical Pharmacokinetics"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0160","doi-asserted-by":"crossref","first-page":"20186","DOI":"10.1074\/jbc.M803020200","article-title":"Reactive nitrogen species is required for the activation of the AMP-activated protein kinase by statin in vivo","volume":"283","author":"Choi","year":"2008","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0165","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1128\/MCB.00666-09","article-title":"Regulation of the intracellular localization of Foxo3a by stress-activated protein kinase signaling pathways in skeletal muscle cells","volume":"30","author":"Clavel","year":"2010","journal-title":"Molecular and Cellular Biology"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0170","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jacl.2012.03.003","article-title":"Understanding Statin Use in America and Gaps in Patient Education (USAGE): An internet-based survey of 10,138 current and former statin users","volume":"6","author":"Cohen","year":"2012","journal-title":"Journal of Clinical Lipidology"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0175","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.taap.2011.05.016","article-title":"Simvastatin induces apoptosis by a Rho-dependent mechanism in cultured cardiac fibroblasts and myofibroblasts","volume":"255","author":"Copaja","year":"2011","journal-title":"Toxicology and Applied Pharmacology"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0180","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1097\/01.ASN.0000138237.42675.45","article-title":"RhoA activation mediates phosphatidylinositol 3-kinase-dependent proliferation of human vascular endothelial cells: An alloimmune mechanism of chronic allograft nephropathy","volume":"15","author":"Coupel","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0185","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1038\/nature06322","article-title":"mTOR controls mitochondrial oxidative function through a YY1-PGC-1alpha transcriptional complex","volume":"450","author":"Cunningham","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0190","doi-asserted-by":"crossref","first-page":"796","DOI":"10.5551\/jat.26856","article-title":"Association between SLCO1B1 521 T>C and 388 A>G polymorphisms and statins effectiveness: A meta-analysis","volume":"22","author":"Dai","year":"2015","journal-title":"Journal of Atherosclerosis and Thrombosis"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0195","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.ahj.2013.01.025","article-title":"Lack of association between SLCO1B1 polymorphisms and clinical myalgia following rosuvastatin therapy","volume":"165","author":"Danik","year":"2013","journal-title":"American Heart Journal"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0200","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/FPC.0000000000000018","article-title":"The SLCO1B1 c.521T>C polymorphism is associated with dose decrease or switching during statin therapy in the Rotterdam Study","volume":"24","author":"de Keyser","year":"2014","journal-title":"Pharmacogenetics and Genomics"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0205","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/clpt.2010.255","article-title":"Common nonsynonymous substitutions in SLCO1B1 predispose to statin intolerance in routinely treated individuals with type 2 diabetes: A go-DARTS study","volume":"89","author":"Donnelly","year":"2011","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0210","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/path.2018","article-title":"Statin therapy induces ultrastructural damage in skeletal muscle in patients without myalgia","volume":"210","author":"Draeger","year":"2006","journal-title":"The Journal of Pathology"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0215","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1113\/jphysiol.2010.188011","article-title":"Exercise intensity-dependent regulation of peroxisome proliferator-activated receptor coactivator-1 mRNA abundance is associated with differential activation of upstream signalling kinases in human skeletal muscle","volume":"588","author":"Egan","year":"2010","journal-title":"The Journal of Physiology"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0225","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.tox.2016.06.015","article-title":"Elucidation of the mechanism of atorvastatin-induced myopathy in a rat model","volume":"359-360","author":"El-Ganainy","year":"2016","journal-title":"Toxicology"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0230","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s00228-014-1661-6","article-title":"Association between statin-induced creatine kinase elevation and genetic polymorphisms in SLCO1B1, ABCB1 and ABCG2","volume":"70","author":"Ferrari","year":"2014","journal-title":"European Journal of Clinical Pharmacology"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0235","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.clpt.2005.08.003","article-title":"The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment","volume":"78","author":"Fiegenbaum","year":"2005","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0240","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1609243","article-title":"A highly durable RNAi therapeutic inhibitor of PCSK9","volume":"376","author":"Fitzgerald","year":"2017","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0245","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1006\/taap.1997.8174","article-title":"HMG CoA reductase inhibitor-induced myotoxicity: pravastatin and lovastatin inhibit the geranylgeranylation of low-molecular-weight proteins in neonatal rat muscle cell culture","volume":"145","author":"Flint","year":"1997","journal-title":"Toxicology and Applied Pharmacology"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0250","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1211\/jpp.57.10.0009","article-title":"Transporter-mediated influx and efflux mechanisms of pitavastatin, a new inhibitor of HMG-CoA reductase","volume":"57","author":"Fujino","year":"2005","journal-title":"The Journal of Pharmacy and Pharmacology"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0255","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.taap.2012.06.020","article-title":"Effect of a high dose of simvastatin on muscle mitochondrial metabolism and calcium signaling in healthy volunteers","volume":"263","author":"Galtier","year":"2012","journal-title":"Toxicology and Applied Pharmacology"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0260","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.tox.2015.01.005","article-title":"Inhibition of prenyltransferase activity by statins in both liver and muscle cell lines is not causative of cytotoxicity","volume":"329","author":"Gee","year":"2015","journal-title":"Toxicology"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0265","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.3390\/ijms16011066","article-title":"Ca2+-dependent regulations and signaling in skeletal muscle: From electro-mechanical coupling to adaptation","volume":"16","author":"Gehlert","year":"2015","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0270","doi-asserted-by":"crossref","first-page":"639","DOI":"10.3109\/00498254.2011.562566","article-title":"Impact of SLCO1B1 (OATP1B1) and ABCG2 (BCRP) genetic polymorphisms and inhibition on LDL-C lowering and myopathy of statins","volume":"41","author":"Generaux","year":"2011","journal-title":"Xenobiotica"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0275","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/clpt.2013.12","article-title":"International transporter consortium commentary on clinically important transporter polymorphisms","volume":"94","author":"Giacomini","year":"2013","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0280","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1007\/s00223-015-0054-x","article-title":"Vitamin D receptor ablation and vitamin D deficiency result in reduced grip strength, altered muscle fibers, and increased myostatin in mice","volume":"97","author":"Girgis","year":"2015","journal-title":"Calcified Tissue International"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0285","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1210\/er.2012-1012","article-title":"The roles of vitamin D in skeletal muscle: Form, function, and metabolism","volume":"34","author":"Girgis","year":"2013","journal-title":"Endocrine Reviews"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0290","doi-asserted-by":"crossref","first-page":"645","DOI":"10.5114\/aoms.2016.59938","article-title":"Molecular mechanisms of statin intolerance","volume":"12","author":"Gluba-Brzozka","year":"2016","journal-title":"Archives of Medical Science"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0295","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.freeradbiomed.2015.04.006","article-title":"Redox modulation of mitochondriogenesis in exercise. Does antioxidant supplementation blunt the benefits of exercise training?","volume":"86","author":"Gomez-Cabrera","year":"2015","journal-title":"Free Radical Biology & Medicine"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0300","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1249\/JES.0000000000000043","article-title":"Skeletal muscle fatigue and decreased efficiency: Two sides of the same coin?","volume":"43","author":"Grassi","year":"2015","journal-title":"Exercise and Sport Sciences Reviews"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0305","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1097\/00002508-200103000-00002","article-title":"The peripheral apparatus of muscle pain: Evidence from animal and human studies","volume":"17","author":"Graven-Nielsen","year":"2001","journal-title":"The Clinical Journal of Pain"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0310","doi-asserted-by":"crossref","first-page":"30107","DOI":"10.1074\/jbc.M705325200","article-title":"The energy sensor AMP-activated protein kinase directly regulates the mammalian FOXO3 transcription factor","volume":"282","author":"Greer","year":"2007","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0315","first-page":"1","article-title":"Prescription cholesterol-lowering medication use in adults aged 40 and over: United States, 2003\u20132012","volume":"177","author":"Gu","year":"2014","journal-title":"NCHS Data Brief"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0320","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1161\/01.RES.83.5.490","article-title":"3-Hydroxy-3-methylglutaryl coenzyme a reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture","volume":"83","author":"Guijarro","year":"1998","journal-title":"Circulation Research"},{"issue":"3 Suppl","key":"10.1016\/j.pharmthera.2017.02.029_bb0325","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.1016\/j.jacl.2014.03.002","article-title":"An assessment by the statin intolerance panel: 2014 update","volume":"8","author":"Guyton","year":"2014","journal-title":"Journal of Clinical Lipidology"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0335","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/iub.572","article-title":"The monocarboxylate transporter family\u2014role and regulation","volume":"64","author":"Halestrap","year":"2012","journal-title":"IUBMB Life"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0340","first-page":"3940","article-title":"The muscle-specific ubiquitin ligase atrogin-1\/MAFbx mediates statin-induced muscle toxicity","volume":"117","author":"Hanai","year":"2007","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0345","doi-asserted-by":"crossref","first-page":"376","DOI":"10.3109\/10799891003641074","article-title":"Regulation of skeletal muscle cell plasticity by the peroxisome proliferator-activated receptor \u03b3 coactivator 1\u03b1","volume":"30","author":"Handschin","year":"2010","journal-title":"Journal of Receptor and Signal Transduction Research"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0350","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1089\/ars.2011.4123","article-title":"Redox regulation of mitochondrial function","volume":"16","author":"Handy","year":"2012","journal-title":"Antioxidants & Redox Signaling"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0355","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1152\/physiol.00044.2005","article-title":"AMPK: A key sensor of fuel and energy status in skeletal muscle","volume":"21","author":"Hardie","year":"2006","journal-title":"Physiology (Bethesda)"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0360","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.1096\/fj.07-8174com","article-title":"Lactate sensitive transcription factor network in L6 cells: Activation of MCT1 and mitochondrial biogenesis","volume":"21","author":"Hashimoto","year":"2007","journal-title":"The FASEB Journal"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb1090","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1249\/MSS.0b013e31815fcb04","article-title":"Mitochondrial lactate oxidation complex and an adaptive role for lactate production","volume":"40","author":"Hashimoto","year":"2008","journal-title":"Med. Sci. Sports Exerc"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0365","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.clpt.2006.02.014","article-title":"Exposure of atorvastatin is unchanged but lactone and acid metabolites are increased several-fold in patients with atorvastatin-induced myopathy","volume":"79","author":"Hermann","year":"2006","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0370","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1053\/j.gastro.2006.02.034","article-title":"Drug and bile acid transporters in rosuvastatin hepatic uptake: Function, expression, and pharmacogenetics","volume":"130","author":"Ho","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0375","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jacl.2011.01.001","article-title":"The C3435T polymorphism in ABCB1 influences atorvastatin efficacy and muscle symptoms in a high-risk vascular cohort","volume":"5","author":"Hoenig","year":"2011","journal-title":"Journal of Clinical Lipidology"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0380","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1242\/jeb.128207","article-title":"Molecular networks in skeletal muscle plasticity","volume":"219","author":"Hoppeler","year":"2016","journal-title":"The Journal of Experimental Biology"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0385","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/2046-7648-3-19","article-title":"Skeletal muscle energy metabolism in environmental hypoxia: Climbing towards consensus","volume":"3","author":"Horscroft","year":"2014","journal-title":"Extreme Physiology & Medicine"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0390","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000001268","article-title":"Association between SLCO1B1 Gene T521C polymorphism and statin-related myopathy risk: A meta-analysis of case-control studies","volume":"94","author":"Hou","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0395","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1161\/CIRCULATIONAHA.115.014026","article-title":"Is cholesteryl ester transfer protein inhibition an effective strategy to reduce cardiovascular risk? CETP as a target to lower CVD risk: Suspension of disbelief?","volume":"132","author":"Hovingh","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0400","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/S1995-7645(14)60154-1","article-title":"RhoA\/ROCK pathway regulates hypoxia-induced myocardial cell apoptosis","volume":"7","author":"Huang","year":"2014","journal-title":"Asian Pacific Journal of Tropical Medicine"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0405","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/sj.clpt.6100190","article-title":"SLCO1B1 (OATP1B1, an uptake transporter) and ABCG2 (BCRP, an efflux transporter) variant alleles and pharmacokinetics of pitavastatin in healthy volunteers","volume":"82","author":"Ieiri","year":"2007","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0410","doi-asserted-by":"crossref","first-page":"156","DOI":"10.3389\/fncel.2015.00156","article-title":"ClC-1 chloride channels: State-of-the-art research and future challenges","volume":"9","author":"Imbrici","year":"2015","journal-title":"Frontiers in Cellular Neuroscience"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0415","doi-asserted-by":"crossref","first-page":"C116","DOI":"10.1152\/ajpcell.00267.2007","article-title":"Interactions between ROS and AMP kinase activity in the regulation of PGC-1alpha transcription in skeletal muscle cells","volume":"296","author":"Irrcher","year":"2009","journal-title":"American Journal of Physiology. Cell Physiology"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0420","doi-asserted-by":"crossref","first-page":"12017","DOI":"10.1073\/pnas.0705070104","article-title":"AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1alpha","volume":"104","author":"J\u00e4ger","year":"2007","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0425","doi-asserted-by":"crossref","first-page":"9183","DOI":"10.1074\/jbc.M114.625715","article-title":"High CO2 levels cause skeletal muscle atrophy via AMP-activated kinase (AMPK), FoxO3a protein, and muscle-specific ring finger protein 1 (MuRF1)","volume":"290","author":"Jaitovich","year":"2015","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0430","doi-asserted-by":"crossref","first-page":"156","DOI":"10.4103\/1947-2714.179133","article-title":"Safety of 50,000\u2013100,000 units of vitamin D3\/week in vitamin D-deficient, hypercholesterolemic patients with reversible statin intolerance","volume":"8","author":"Jetty","year":"2016","journal-title":"North American Journal of Medical Sciences"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0435","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1186\/s40064-016-2912-z","article-title":"Association between SLCO1B1 \u2212521T>C and \u2212388A>G polymorphisms and risk of statin-induced adverse drug reactions: A meta-analysis","volume":"5","author":"Jiang","year":"2016","journal-title":"SpringerPlus"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0440","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.taap.2004.04.010","article-title":"Statins induce apoptosis in rat and human myotube cultures by inhibiting protein geranylgeranylation but not ubiquinone","volume":"200","author":"Johnson","year":"2004","journal-title":"Toxicology and Applied Pharmacology"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0445","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.biochi.2015.10.022","article-title":"Creatine biosynthesis and transport in health and disease","volume":"119","author":"Joncquel-Chevalier Curt","year":"2015","journal-title":"Biochimie"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0450","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.jacl.2016.02.016","article-title":"Gender differences in side effects and attitudes regarding statin use in the Understanding Statin Use in America and Gaps in Patient Education (USAGE) study","volume":"10","author":"Karalis","year":"2016","journal-title":"Journal of Clinical Lipidology"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0455","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1007\/s00018-006-6235-z","article-title":"Toxicity of statins on rat skeletal muscle mitochondria","volume":"63","author":"Kaufmann","year":"2006","journal-title":"Cellular and Molecular Life Sciences"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0460","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0149082","article-title":"endurance exercise enhances the effect of strength training on muscle fiber size and protein expression of Akt and mTOR","volume":"11","author":"Kazior","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0465","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/978-3-642-14541-4_8","article-title":"Multidrug resistance proteins (MRPs, ABCCs): Importance for pathophysiology and drug therapy","volume":"201","author":"Keppler","year":"2011","journal-title":"Handbook of Experimental Pharmacology"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0470","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.2217\/pgs.09.85","article-title":"Different effects of the ABCG2 c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin","volume":"10","author":"Keskitalo","year":"2009","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0475","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/clpt.2009.79","article-title":"ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin","volume":"86","author":"Keskitalo","year":"2009","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0480","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1365-2125.2009.03440.x","article-title":"No significant effect of ABCB1 haplotypes on the pharmacokinetics of fluvastatin, pravastatin, lovastatin, and rosuvastatin","volume":"68","author":"Keskitalo","year":"2009","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0485","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/clpt.2008.25","article-title":"ABCB1 haplotypes differentially affect the pharmacokinetics of the acid and lactone forms of simvastatin and atorvastatin","volume":"84","author":"Keskitalo","year":"2008","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0490","doi-asserted-by":"crossref","first-page":"86","DOI":"10.4103\/1947-2714.153919","article-title":"Statin intolerance because of myalgia, myositis, myopathy, or myonecrosis can in most cases be safely resolved by vitamin D supplementation","volume":"7","author":"Khayznikov","year":"2015","journal-title":"North American Journal of Medical Sciences"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0495","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1016\/j.xphs.2016.01.014","article-title":"Involvement of monocarboxylate transporter 4 expression in statin-induced cytotoxicity","volume":"105","author":"Kikutani","year":"2016","journal-title":"Journal of Pharmaceutical Sciences"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0500","first-page":"106","article-title":"Akt: Versatile mediator of cell survival and beyond","volume":"35","author":"Kim","year":"2002","journal-title":"Journal of Biochemistry and Molecular Biology"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0505","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1126\/science.1135308","article-title":"A \u201csilent\u201d polymorphism in the MDR1 gene changes substrate specificity","volume":"315","author":"Kimchi-Sarfaty","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0510","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s12576-013-0290-7","article-title":"Effect of AMPK activation on monocarboxylate transporter (MCT)1 and MCT4 in denervated muscle","volume":"64","author":"Kitaoka","year":"2014","journal-title":"The Journal of Physiological Sciences"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0515","doi-asserted-by":"crossref","first-page":"97","DOI":"10.2147\/PGPM.S86013","article-title":"Pharmacogenomics of statins: Understanding susceptibility to adverse effects","volume":"9","author":"Kitzmiller","year":"2016","journal-title":"Pharmacogenomics and Personalized Medicine"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0520","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1161\/CIRCRESAHA.109.203596","article-title":"Human skeletal muscle drug transporters determine local exposure and toxicity of statins","volume":"106","author":"Knauer","year":"2010","journal-title":"Circulation Research"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0525","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1248\/yakushi.15-00199","article-title":"Role of monocarboxylate transporter in statin-induced cytotoxicity","volume":"135","author":"Kobayashi","year":"2015","journal-title":"Yakugaku Zasshi"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0530","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1248\/bpb.28.1197","article-title":"Transport mechanism for l-lactic acid in human myocytes using human prototypic embryonal rhabdomyosarcoma cell line (RD cells)","volume":"28","author":"Kobayashi","year":"2005","journal-title":"Biological & Pharmaceutical Bulletin"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0535","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1248\/yakushi.132.609","article-title":"Effects of acidification and alkalinization agents on statins-induced muscle toxicity","volume":"132","author":"Kobayashi","year":"2012","journal-title":"Yakugaku Zasshi"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0540","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ijpharm.2006.02.043","article-title":"Inhibitory effects of statins on human monocarboxylate transporter 4","volume":"317","author":"Kobayashi","year":"2006","journal-title":"International Journal of Pharmaceutics"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0545","first-page":"68","article-title":"The creatine kinase response to resistance exercise","volume":"14","author":"Koch","year":"2014","journal-title":"Journal of Musculoskeletal & Neuronal Interactions"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0550","doi-asserted-by":"crossref","first-page":"14734","DOI":"10.1074\/jbc.M808664200","article-title":"Regulation of Rac1 by simvastatin in endothelial cells: differential roles of AMP-activated protein kinase and calmodulin-dependent kinase kinase-beta","volume":"284","author":"Kou","year":"2009","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0555","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/00008571-200308000-00006","article-title":"Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene","volume":"13","author":"Kroetz","year":"2003","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0560","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1124\/dmd.114.058412","article-title":"Prediction of organic anion-transporting polypeptide 1B1- and 1B3-mediated hepatic uptake of statins based on transporter protein expression and activity data","volume":"42","author":"Kunze","year":"2014","journal-title":"Drug Metabolism and Disposition"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0565","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.freeradbiomed.2011.10.449","article-title":"Simvastatin impairs ADP-stimulated respiration and increases mitochondrial oxidative stress in primary human skeletal myotubes","volume":"52","author":"Kwak","year":"2012","journal-title":"Free Radical Biology & Medicine"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0570","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.2217\/pgs.13.115","article-title":"Effects of polymorphisms in ABCG2, SLCO1B1, SLC10A1 and CYP2C9\/19 on plasma concentrations of rosuvastatin and lipid response in Chinese patients","volume":"14","author":"Lee","year":"2013","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0575","doi-asserted-by":"crossref","first-page":"163","DOI":"10.2217\/pgs.15.158","article-title":"Seventeen years of statin pharmacogenetics: A systematic review","volume":"17","author":"Leusink","year":"2016","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0580","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1124\/jpet.106.118331","article-title":"Fluvastatin and atorvastatin affect calcium homeostasis of rat skeletal muscle fibers in vivo and in vitro by impairing the sarcoplasmic reticulum\/mitochondria Ca2+-release system","volume":"321","author":"Liantonio","year":"2007","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0585","doi-asserted-by":"crossref","first-page":"77","DOI":"10.4161\/derm.2.2.13509","article-title":"The role of vitamin D and SLCO1B1\u22175 gene polymorphism in statin-associated myalgias","volume":"2","author":"Linde","year":"2010","journal-title":"Dermato-Endocrinology"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0590","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1056\/NEJMoa0801936","article-title":"SLCO1B1 variants and statin-induced myopathy\u2014A genomewide study","volume":"359","author":"Link","year":"2008","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0595","doi-asserted-by":"crossref","DOI":"10.1111\/cpf.12375","article-title":"Statin use may reduce lower extremity peak force via reduced engagement in muscle-strengthening activities","author":"Loenneke","year":"2016","journal-title":"Clinical Physiology and Functional Imaging"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0600","first-page":"775","article-title":"The effect of Na+\/taurocholate cotransporting polypeptide (NTCP) c.800C>T polymorphism on rosuvastatin pharmacokinetics in Chinese healthy males","volume":"69","author":"Lou","year":"2014","journal-title":"Pharmazie"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0605","first-page":"93","article-title":"Critical role of mitochondrial ROS is dependent on their site of production on the electron transport chain in ischemic heart","volume":"6","author":"Madungwe","year":"2016","journal-title":"American Journal of Cardiovascular Disease"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0610","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.clpt.2006.01.011","article-title":"Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril","volume":"79","author":"Maeda","year":"2006","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0615","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s10974-015-9439-8","article-title":"Skeletal muscle atrophy: Disease-induced mechanisms may mask disuse atrophy","volume":"36","author":"Malavaki","year":"2015","journal-title":"Journal of Muscle Research and Cell Motility"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0620","doi-asserted-by":"crossref","first-page":"6389","DOI":"10.1113\/jphysiol.2012.238022","article-title":"Pharmacological activation of the pyruvate dehydrogenase complex reduces statin-mediated upregulation of FOXO gene targets and protects against statin myopathy in rodents","volume":"590","author":"Mallinson","year":"2012","journal-title":"The Journal of Physiology"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0625","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1113\/jphysiol.2008.164699","article-title":"Blunted Akt\/FOXO signalling and activation of genes controlling atrophy and fuel use in statin myopathy","volume":"587","author":"Mallinson","year":"2009","journal-title":"The Journal of Physiology"},{"issue":"7 Suppl","key":"10.1016\/j.pharmthera.2017.02.029_bb0630","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1016\/j.cjca.2016.01.003","article-title":"Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian consensus working group update","volume":"32","author":"Mancini","year":"2016","journal-title":"The Canadian Journal of Cardiology"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0635","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s40798-015-0033-9","article-title":"Influence of the MCT1 rs1049434 on indirect muscle disorders\/injuries in elite football players","volume":"1","author":"Massidda","year":"2015","journal-title":"Sports Medicine - Open"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0640","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1006\/taap.1995.1058","article-title":"In vitro myotoxicity of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, pravastatin, lovastatin, and simvastatin, using neonatal rat skeletal myocytes","volume":"131","author":"Masters","year":"1995","journal-title":"Toxicology and Applied Pharmacology"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0645","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/(SICI)1097-4598(200001)23:1<90::AID-MUS12>3.0.CO;2-M","article-title":"Mutations in MCT1 cDNA in patients with symptomatic deficiency in lactate transport","volume":"23","author":"Merezhinskaya","year":"2000","journal-title":"Muscle & Nerve"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0650","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.clinthera.2014.02.023","article-title":"Low vitamin D as a risk factor for the development of myalgia in patients taking high-dose simvastatin: A retrospective review","volume":"36","author":"Mergenhagen","year":"2014","journal-title":"Clinical Therapeutics"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0655","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/978-3-642-14541-4_9","article-title":"In vitro and in vivo evidence for the importance of breast cancer resistance protein transporters (BCRP\/MXR\/ABCP\/ABCG2)","volume":"201","author":"Meyer zu Schwabedissen","year":"2011","journal-title":"Handbook of Experimental Pharmacology"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0660","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ijcard.2014.10.118","article-title":"Analysis of vitamin D levels in patients with and without statin-associated myalgia \u2014 A systematic review and meta-analysis of 7 studies with 2420 patients","volume":"178","author":"Michalska-Kasiczak","year":"2015","journal-title":"International Journal of Cardiology"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0665","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0301-0082(98)00048-3","article-title":"The induction of pain: an integrative review","volume":"57","author":"Millan","year":"1999","journal-title":"Progress in Neurobiology"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0670","doi-asserted-by":"crossref","first-page":"803","DOI":"10.2217\/pgs.15.47","article-title":"ABCG2 gene polymorphisms as risk factors for atorvastatin adverse reactions: A case-control study","volume":"16","author":"Miro\u0161evi\u0107 Skvrce","year":"2015","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0675","doi-asserted-by":"crossref","first-page":"E11","DOI":"10.1503\/cmaj.081785","article-title":"Association between statin-associated myopathy and skeletal muscle damage","volume":"181","author":"Mohaupt","year":"2009","journal-title":"CMAJ"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0680","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.freeradbiomed.2016.01.012","article-title":"AMPK signaling in skeletal muscle during exercise: Role of reactive oxygen and nitrogen species","volume":"98","author":"Morales-Alamo","year":"2016","journal-title":"Free Radical Biology & Medicine"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0685","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.braindev.2003.12.009","article-title":"Dichloroacetate treatment for mitochondrial cytopathy: Long-term effects in MELAS","volume":"26","author":"Mori","year":"2004","journal-title":"Brain and Development"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0690","doi-asserted-by":"crossref","first-page":"121","DOI":"10.5551\/jat.12.121","article-title":"Analysis of the global RNA expression profiles of skeletal muscle cells treated with statins","volume":"12","author":"Morikawa","year":"2005","journal-title":"Journal of Atherosclerosis and Thrombosis"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0695","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.atherosclerosis.2014.11.012","article-title":"Vitamin D status modifies the association between statin use and musculoskeletal pain: A population based study","volume":"238","author":"Morioka","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0700","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.bcp.2009.12.007","article-title":"Effect of simvastatin on cholesterol metabolism in C2C12 myotubes and HepG2 cells, and consequences for statin-induced myopathy","volume":"79","author":"Mullen","year":"2010","journal-title":"Biochemical Pharmacology"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0705","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1016\/j.bbamcr.2011.07.019","article-title":"Susceptibility to simvastatin-induced toxicity is partly determined by mitochondrial respiration and phosphorylation state of Akt","volume":"1813","author":"Mullen","year":"2011","journal-title":"Biochimica et Biophysica Acta"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0710","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.drudis.2016.09.001","article-title":"Statin-associated myopathy and the quest for biomarkers: can we effectively predict statin-associated muscle symptoms?","volume":"22","author":"Muntean","year":"2017","journal-title":"Drug Discovery Today"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0715","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1152\/japplphysiol.01362.2011","article-title":"Coenzyme Q10 reverses mitochondrial dysfunction in atorvastatin-treated mice and increases exercise endurance","volume":"113","author":"Muraki","year":"2012","journal-title":"Journal of Applied Physiology (1985)"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0720","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0378-5173(03)00318-1","article-title":"Transport mechanism for lovastatin acid in bovine kidney NBL-1 cells: kinetic evidences imply involvement of monocarboxylate transporter 4","volume":"262","author":"Nagasawa","year":"2003","journal-title":"International Journal of Pharmaceutics"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0725","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1002\/jps.10246","article-title":"Monocarboxylate transporter mediates uptake of lovastatin acid in rat cultured mesangial cells","volume":"91","author":"Nagasawa","year":"2002","journal-title":"Journal of Pharmaceutical Sciences"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0730","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.2217\/pgs-2016-0071","article-title":"Rare variants in known and novel candidate genes predisposing to statin-associated myopathy","volume":"17","author":"Ne\u0159oldov\u00e1","year":"2016","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0735","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.clpt.2006.06.010","article-title":"SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin","volume":"80","author":"Niemi","year":"2006","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0745","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/gm405","article-title":"Genetics is a major determinant of expression of the human hepatic uptake transporter OATP1B1, but not of OATP1B3 and OATP2B1","volume":"5","author":"Nies","year":"2013","journal-title":"Genome Medicine"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0750","doi-asserted-by":"crossref","first-page":"196","DOI":"10.2133\/dmpk.DMPK-12-RG-068","article-title":"Impact of ABCC2, ABCG2 and SLCO1B1 polymorphisms on the pharmacokinetics of pitavastatin in humans","volume":"28","author":"Oh","year":"2013","journal-title":"Drug Metabolism and Pharmacokinetics"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0755","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.bbrc.2015.09.065","article-title":"Skeletal muscle-specific HMG-CoA reductase knockout mice exhibit rhabdomyolysis: A model for statin-induced myopathy","volume":"466","author":"Osaki","year":"2015","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0760","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/bcpt.12482","article-title":"Low vitamin D levels and genetic polymorphism in the vitamin D receptor are associated with increased risk of statin-induced myopathy","volume":"118","author":"Ovesj\u00f6","year":"2016","journal-title":"Basic & Clinical Pharmacology & Toxicology"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0765","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.clpt.2005.03.006","article-title":"High-dose statins and skeletal muscle metabolism in humans: A randomized, controlled trial","volume":"78","author":"P\u00e4iv\u00e4","year":"2005","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0770","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0088877","article-title":"Association of vitamin D and incident statin induced myalgia\u2014A retrospective cohort study","volume":"9","author":"Palamaner Subash Shantha","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0775","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1097\/01.fpc.0000230416.82349.90","article-title":"SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid","volume":"16","author":"Pasanen","year":"2006","journal-title":"Pharmacogenetics and Genomics"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0780","first-page":"1","article-title":"Severity of statin-induced adverse effects on muscle and associated conditions: data from the DAMA study","author":"Pedro-Botet","year":"2016","journal-title":"Expert Opinion on Drug Safety"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0785","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.reuma.2016.03.009","article-title":"Is there really a relationship between serum vitamin D (25OHD) levels and the musculoskeletal pain associated with statin intake? A systematic review","volume":"12","author":"Pereda","year":"2016","journal-title":"Reumatolog\u00eda Cl\u00ednica"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0790","doi-asserted-by":"crossref","first-page":"581","DOI":"10.7326\/0003-4819-137-7-200210010-00009","article-title":"Statin-associated myopathy with normal creatine kinase levels","volume":"137","author":"Phillips","year":"2002","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0795","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1111\/j.1476-5381.2008.00079.x","article-title":"Statins and fenofibrate affect skeletal muscle chloride conductance in rats by differently impairing ClC-1 channel regulation and expression","volume":"156","author":"Pierno","year":"2009","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0800","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1113\/expphysiol.2013.075812","article-title":"Exogenously applied muscle metabolites synergistically evoke sensations of muscle fatigue and pain in human subjects","volume":"99","author":"Pollak","year":"2014","journal-title":"Experimental Physiology"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0805","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/clpt.2014.125","article-title":"The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update","volume":"96","author":"Ramsey","year":"2014","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0810","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0815","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1517\/17425251003713519","article-title":"Efflux and uptake transporters as determinants of statin response","volume":"6","author":"Rodrigues","year":"2010","journal-title":"Expert Opinion on Drug Metabolism & Toxicology"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0820","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1096\/fj.13-240168","article-title":"Scavenger receptor CD36 mediates inhibition of cholesterol synthesis via activation of the PPAR\u03b3\/PGC-1\u03b1 pathway and Insig1\/2 expression in hepatocytes","volume":"28","author":"Rodrigue-Way","year":"2014","journal-title":"The FASEB Journal"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0825","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.pain.2004.09.017","article-title":"Increase in muscle nociceptive substances and anaerobic metabolism in patients with trapezius myalgia: microdialysis in rest and during exercise","volume":"112","author":"Rosendal","year":"2004","journal-title":"Pain"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0830","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1152\/jappl.1988.64.6.2306","article-title":"Effect of metabolic products of muscular contraction on discharge of group III and IV afferents","volume":"64","author":"Rotto","year":"1988","journal-title":"Journal of Applied Physiology (1985)"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0835","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","article-title":"Efficacy and safety of evolocumab in reducing lipids and cardiovascular events","volume":"372","author":"Sabatine","year":"2015","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0840","article-title":"Impact of statin therapy on plasma vitamin D levels: A systematic review and meta-analysis","author":"Sahebkar","year":"2016","journal-title":"Current Pharmaceutical Design"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0845","doi-asserted-by":"crossref","first-page":"4087","DOI":"10.1096\/fj.07-8713com","article-title":"Rab-small GTPases are involved in fluvastatin and pravastatin-induced vacuolation in rat skeletal myofibers","volume":"21","author":"Sakamoto","year":"2007","journal-title":"The FASEB Journal"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0850","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1002\/mnfr.201300074","article-title":"1,25(OH)2-vitamin D3 enhances the stimulating effect of leucine and insulin on protein synthesis rate through Akt\/PKB and mTOR mediated pathways in murine C2C12 skeletal myotubes","volume":"57","author":"Salles","year":"2013","journal-title":"Molecular Nutrition & Food Research"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0855","doi-asserted-by":"crossref","first-page":"16260","DOI":"10.1073\/pnas.0607795103","article-title":"PGC-1alpha protects skeletal muscle from atrophy by suppressing FoxO3 action and atrophy-specific gene transcription","volume":"103","author":"Sandri","year":"2006","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0860","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s00228-011-1125-1","article-title":"SLCO1B1 haplotypes are not associated with atorvastatin-induced myalgia in Brazilian patients with familial hypercholesterolemia","volume":"68","author":"Santos","year":"2012","journal-title":"European Journal of Clinical Pharmacology"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0865","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.pcad.2016.07.009","article-title":"Statin intolerance: A literature review and management strategies","volume":"59","author":"Saxon","year":"2016","journal-title":"Progress in Cardiovascular Diseases"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0870","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1472-8206.2004.00299.x","article-title":"Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update","volume":"19","author":"Schachter","year":"2005","journal-title":"Fundamental & Clinical Pharmacology"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0875","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/sj.clpt.6100124","article-title":"Decreased skeletal muscle mitochondrial DNA in patients treated with high-dose simvastatin","volume":"81","author":"Schick","year":"2007","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0880","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.cmet.2015.08.002","article-title":"Statin-induced myopathy is associated with mitochondrial complex III inhibition","volume":"22","author":"Schirris","year":"2015","journal-title":"Cell Metabolism"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0885","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2133\/dmpk.DMPK-10-RG-073","article-title":"Intestinal absorption of HMG-CoA reductase inhibitor pitavastatin mediated by organic anion transporting polypeptide and P-glycoprotein\/multidrug resistance 1","volume":"26","author":"Shirasaka","year":"2011","journal-title":"Drug Metabolism and Pharmacokinetics"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0890","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.pharmthera.2006.03.003","article-title":"Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: Drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions","volume":"112","author":"Shitara","year":"2006","journal-title":"Pharmacology & Therapeutics"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0895","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.clinthera.2006.01.005","article-title":"Statin-related adverse events: A meta-analysis","volume":"28","author":"Silva","year":"2006","journal-title":"Clinical Therapeutics"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0900","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.taap.2012.01.008","article-title":"Muscle mitochondrial metabolism and calcium signaling impairment in patients treated with statins","volume":"259","author":"Sirvent","year":"2012","journal-title":"Toxicology and Applied Pharmacology"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0905","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.bbrc.2005.02.070","article-title":"Simvastatin triggers mitochondria-induced Ca2+ signaling alteration in skeletal muscle","volume":"329","author":"Sirvent","year":"2005","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0910","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.12659\/MSM.890777","article-title":"Coenzyme Q10 supplementation decreases statin-related mild-to-moderate muscle symptoms: a randomized clinical study","volume":"20","author":"Skarlovnik","year":"2014","journal-title":"Medical Science Monitor"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0915","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/bcpt.12375","article-title":"Statin-induced myopathy and ubiquinone levels in serum \u2014 results from a prospective, observational study","volume":"117","author":"Skilving","year":"2015","journal-title":"Basic & Clinical Pharmacology & Toxicology"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0920","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1007\/s00228-016-2105-2","article-title":"Statin-induced myopathy in a usual care setting-a prospective observational study of gender differences","volume":"72","author":"Skilving","year":"2016","journal-title":"European Journal of Clinical Pharmacology"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0925","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1002\/mus.20619","article-title":"Elevated skeletal muscle phosphodiesters in adults using statin medications","volume":"34","author":"Slade","year":"2006","journal-title":"Muscle & Nerve"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0930","doi-asserted-by":"crossref","first-page":"E698","DOI":"10.1152\/ajpendo.00747.2007","article-title":"CaMK activation during exercise is required for histone hyperacetylation and MEF2A binding at the MEF2 site on the Glut4 gene","volume":"295","author":"Smith","year":"2008","journal-title":"American Journal of Physiology. Endocrinology and Metabolism"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0935","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.cell.2006.09.024","article-title":"Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators","volume":"127","author":"St-Pierre","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0940","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.33549\/physiolres.933284","article-title":"Large copy-number variations in patients with statin-associated myopathy affecting statin myopathy-related loci","volume":"65","author":"Str\u00e1neck\u00fd","year":"2016","journal-title":"Physiological Research"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0945","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","article-title":"Statin-associated muscle symptoms: impact on statin therapy-european atherosclerosis society consensus panel statement on assessment, aetiology and management","volume":"36","author":"Stroes","year":"2015","journal-title":"European Heart Journal"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0950","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s12944-015-0114-2","article-title":"ABCB1 C3435T polymorphism and the lipid-lowering response in hypercholesterolemic patients on statins: a meta-analysis","volume":"14","author":"Su","year":"2015","journal-title":"Lipids in Health and Disease"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0955","doi-asserted-by":"crossref","first-page":"8738","DOI":"10.1073\/pnas.1212976110","article-title":"Skeletal muscle PGC-1\u03b1 controls whole-body lactate homeostasis through estrogen-related receptor \u03b1-dependent activation of LDH B and repression of LDH A","volume":"110","author":"Summermatter","year":"2013","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0960","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1161\/CIRCULATIONAHA.106.630194","article-title":"Statins activate AMP-activated protein kinase in vitro and in vivo","volume":"114","author":"Sun","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0965","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.trsl.2015.01.007","article-title":"Evidence for metabolic aberrations in asymptomatic persons with type 2 diabetes after initiation of simvastatin therapy","volume":"166","author":"Suneja","year":"2015","journal-title":"Translational Research"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0970","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1096\/fj.201500128","article-title":"Skeletal muscle PGC-1\u03b1 modulates systemic ketone body homeostasis and ameliorates diabetic hyperketonemia in mice","volume":"30","author":"Svensson","year":"2016","journal-title":"The FASEB Journal"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0975","doi-asserted-by":"crossref","first-page":"685328","DOI":"10.1155\/2011\/685328","article-title":"Physiology and pathophysiology of CLC-1: Mechanisms of a chloride channel disease, myotonia","volume":"2011","author":"Tang","year":"2011","journal-title":"Journal of Biomedicine & Biotechnology"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0980","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.atherosclerosis.2014.12.016","article-title":"A randomized trial of coenzyme Q10 in patients with confirmed statin myopathy","volume":"238","author":"Taylor","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0985","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s40266-015-0290-9","article-title":"Statins for primary prevention of cardiovascular disease in elderly patients: Systematic review and meta-analysis","volume":"32","author":"Teng","year":"2015","journal-title":"Drugs & Aging"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0990","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s00228-016-2011-7","article-title":"Prevalence of statin-drug interactions in older people: A systematic review","volume":"72","author":"Thai","year":"2016","journal-title":"European Journal of Clinical Pharmacology"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb0995","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1177\/37.2.2463300","article-title":"Immunohistochemical localization in normal tissues of different epitopes in the multidrug transport protein P170: Evidence for localization in brain capillaries and cross reactivity of one antibody with a muscle protein","volume":"37","author":"Thiebaut","year":"1989","journal-title":"The Journal of Histochemistry and Cytochemistry"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb1000","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1152\/japplphysiol.01057.2004","article-title":"Monocarboxylate transporters, blood lactate removal after supramaximal exercise, and fatigue indexes in humans","volume":"98","author":"Thomas","year":"2005","journal-title":"Journal of Applied Physiology (1985)"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb1005","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1097\/FPC.0000000000000148","article-title":"SLCO1B1 polymorphism markedly affects the pharmacokinetics of lovastatin acid","volume":"25","author":"Tornio","year":"2015","journal-title":"Pharmacogenetics and Genomics"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb1010","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1161\/01.ATV.0000190608.28704.71","article-title":"Changes in ubiquitin proteasome pathway gene expression in skeletal muscle with exercise and statins","volume":"25","author":"Urso","year":"2005","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb1015","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1139\/h04-022","article-title":"The myofibrillar complex and fatigue: A review","volume":"29","author":"Vandenboom","year":"2004","journal-title":"Canadian Journal of Applied Physiology"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb1020","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.bbabio.2013.10.011","article-title":"Role of mitochondria-cytoskeleton interactions in respiration regulation and mitochondrial organization in striated muscles","volume":"1837","author":"Varikmaa","year":"2014","journal-title":"Biochimica et Biophysica Acta"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb1025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejphar.2013.04.009","article-title":"Ubiquinol rescues simvastatin-suppression of mitochondrial content, function and metabolism: Implications for statin-induced rhabdomyolysis","volume":"711","author":"Vaughan","year":"2013","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb1030","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1016\/j.jacc.2009.04.053","article-title":"The SLCO1B1\u22175 genetic variant is associated with statin-induced side effects","volume":"54","author":"Voora","year":"2009","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb1035","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s11010-015-2608-7","article-title":"Effects of ageing on expression of the muscle-specific E3 ubiquitin ligases and Akt-dependent regulation of Foxo transcription factors in skeletal muscle","volume":"412","author":"Wagatsuma","year":"2016","journal-title":"Molecular and Cellular Biochemistry"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb1040","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/jep.12462","article-title":"Statin prescribing according to gender, age and indication: What about the benefit-risk balance?","volume":"22","author":"Wallach-Kildemoes","year":"2016","journal-title":"Journal of Evaluation in Clinical Practice"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb1045","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1124\/jpet.115.225045","article-title":"Marked alteration of rosuvastatin pharmacokinetics in healthy Chinese with ABCG2 34G>A and 421C>A homozygote or compound heterozygote","volume":"354","author":"Wan","year":"2015","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb1050","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/01213011-200506000-00007","article-title":"Relative impact of CYP3A genotype and concomitant medication on the severity of atorvastatin-induced muscle damage","volume":"15","author":"Wilke","year":"2005","journal-title":"Pharmacogenetics and Genomics"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb1060","doi-asserted-by":"crossref","first-page":"526","DOI":"10.7326\/0003-4819-158-7-201304020-00004","article-title":"Discontinuation of statins in routine care settings: A cohort study","volume":"158","author":"Zhang","year":"2013","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb1065","doi-asserted-by":"crossref","DOI":"10.14814\/phy2.12008","article-title":"Multiple signaling pathways regulate contractile activity-mediated PGC-1\u03b1 gene expression and activity in skeletal muscle cells","volume":"2","author":"Zhang","year":"2014","journal-title":"Physiological Reports"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb1070","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1096\/fj.09-151480","article-title":"FOXO3a mediates signaling crosstalk that coordinates ubiquitin and atrogin-1\/MAFbx expression during glucocorticoid-induced skeletal muscle atrophy","volume":"24","author":"Zheng","year":"2010","journal-title":"The FASEB Journal"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb1075","first-page":"187","article-title":"CYP2C9\u22173(1075A>C), ABCB1 and SLCO1B1 genetic polymorphisms and gender are determinants of inter-subject variability in pitavastatin pharmacokinetics","volume":"68","author":"Zhou","year":"2013","journal-title":"Pharmazie"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb1080","first-page":"124","article-title":"Simvastatin pharmacokinetics in healthy Chinese subjects and its relations with CYP2C9, CYP3A5, ABCB1, ABCG2 and SLCO1B1 polymorphisms","volume":"68","author":"Zhou","year":"2013","journal-title":"Pharmazie"},{"key":"10.1016\/j.pharmthera.2017.02.029_bb1085","first-page":"129","article-title":"ABCB1 gene polymorphisms, ABCB1 haplotypes and ABCG2 c.421c>A are determinants of inter-subject variability in rosuvastatin pharmacokinetics","volume":"68","author":"Zhou","year":"2013","journal-title":"Pharmazie"}],"container-title":["Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725817300438?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725817300438?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,2]],"date-time":"2020-10-02T07:08:16Z","timestamp":1601622496000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725817300438"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":213,"alternative-id":["S0163725817300438"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2017.02.029","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Myotoxicity of statins: Mechanism of action","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2017.02.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}